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Abstract
Adverse posttraumatic neuropsychiatric sequelae (APNS) are common among civilian trauma 
survivors and military veterans. These APNS, as traditionally classified, include posttraumatic 
stress, post-concussion syndrome, depression, and regional or widespread pain. Traditional 
classifications have come to hamper scientific progress because they artificially fragment APNS 
into siloed, syndromic diagnoses unmoored to discrete components of brain functioning and 
studied in isolation. These limitations in classification and ontology slow the discovery of 
pathophysiologic mechanisms, biobehavioral markers, risk prediction tools, and preventive/
treatment interventions. Progress in overcoming these limitations has been challenging, because 
such progress would require studies that both evaluate a broad spectrum of posttraumatic sequelae 
(to overcome fragmentation) and also perform in-depth biobehavioral evaluation (to index 
sequelae to domains of brain function). This article summarizes the methods of the Advancing 
Understanding of RecOvery afteR traumA (AURORA) Study. AURORA conducts a large scale (n 
= 5,000 target sample) in-depth assessment of APNS development using a state-of-the-art battery 
of self-report, neurocognitive, physiologic, digital phenotyping, psychophysical, neuroimaging, 
and genomic assessments, beginning in the early aftermath of trauma and continuing for one year. 
The goals of AURORA are to achieve improved phenotypes, prediction tools, and understanding 
of molecular mechanisms to inform the future development and testing of preventive and treatment 
interventions.
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Introduction
Adverse posttraumatic neuropsychiatric sequelae (APNS) are common among civilian 
trauma survivors and military service members.1–4 These APNS, as traditionally classified, 
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include posttraumatic stress (PTS), depression, post-concussion syndrome (PCS), and 
regional or widespread pain. Studies using these traditional classifications have yielded 
many advances, yet flaws in these classifications increasingly hamper scientific progress for 
several reasons. First, traditional APNS classifications are not indexed to specific biological 
processes or components of brain functioning. Instead, classification boundaries evolved 
based on factors such as the traditional bailiwicks of specific medical specialties (e.g., PTS: 
psychiatry, PCS: neurosurgery, pain: anesthesiology). Second, individual syndromes (which 
are typically studied in isolation) do not accurately reflect actual posttraumatic 
neuropsychiatric phenotypes. Most trauma survivors experience complex patterns of 
overlapping/co-occurring symptoms across multiple traditional classifications, and 
increasing evidence indicates that symptoms across classifications can share an interwoven/
overlapping neurobiological substrate.
The consequences of these limitations in classification are that most contemporary studies of 
APNS consist of the evaluation of isolated, arbitrarily-demarcated syndromes, representing 
only a fragment of a trauma survivor’s posttraumatic neuropsychiatric sequelae. Such 
outcome fragments are often evaluated by different medical specialties, who collect very 
different datasets to test disparate pathogenic models (e.g., stress-related neurobiology 
(PTS), mechanical brain injury (PCS), soft tissue injury (pain)). Fundamental changes in 
APNS classification and study are urgently needed (Figure 1).
Progress to improve classification and ontology of APNS has been challenging, because 
such progress would require studies that both evaluate a broad spectrum of posttraumatic 
sequelae (to overcome fragmentation) and also perform in-depth biobehavioral evaluations 
(to index components of the trauma survivor’s experience to specific domains of brain 
functioning). Because many of the critical changes in neurobiology and brain function that 
establish APNS appear to occur in the initial days and weeks after trauma exposure (TE),5–7 
such studies would need to enroll participants in the early aftermath of trauma and perform 
serial longitudinal evaluations. The great expense and formidable logistical challenges posed 
by such studies have limited their conduct.
To help overcome these limitations, the National Institutes of Mental Health, joined by the 
US Army Medical Research and Material Command, The One Mind Foundation, the Stanley 
Center for Psychiatric Research, and The Mayday Fund, together with corporate partners 
including Verily Life Sciences and Mindstrong Health, developed the Advancing 
Understanding of RecOvery afteR traumA (AURORA) study. AURORA is a large-scale 
emergency department (ED)-based study (n = 5,000 target sample) that uses adaptive 
sampling methods to collect a combination of genomic, neuroimaging, psychophysical, 
physiological, neurocognitive, digital phenotyping, and self-report data from trauma 
survivors, beginning in the early aftermath of trauma and continuing for one year (Table 1, 
Figures 2, 3). The overarching goal of the AURORA Study is to provide a well-powered, 
many-layered publicly available dataset capable of helping to address the above barriers and 
advancing discovery.
Within this overarching goal, analytic efforts during the award period will focus on three 
broad aims. The first aim is to identify/classify common, discrete, homogeneous APNS 
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using and/or building on the Research Domain Criteria (RDoC) classification system 
(https://www.nimh.nih.gov/research-priorities/rdoc/index.shtm). Discrete APNS will be 
characterized by both self-report and biomarker data (i.e., biomarkers from different RDoC 
“units of analysis”). Next, after identifying discrete APNS, multidimensional phenotypes 
will be identified that consist of the most frequent “baskets” of discrete APNS (across 
traditional APNS domains) that individual trauma survivors develop. Such multidimensional 
classification is essential to more accurately represent the individual trauma survivor 
experience, to create a common phenotypic “denominator” across specialties and NIH 
institutes funding research (e.g., to allow testing of competing theories of pathogenesis), and 
to improve intervention testing via more accurate target group identification. The second 
AURORA Study aim is to test hypotheses regarding the influence of specific pre-trauma, 
trauma-related, and recovery-related factors on the onset, severity, and course of discrete and 
multidimensional APNS outcomes. The third and final AURORA aim is to develop tiered 
clinical decision support algorithms for multidimensional APNS outcomes, using ensemble 
machine learning methods and the range of biobehavioral study data collected. In order to 
achieve the best possible dissemination/reach, these decision support algorithms will be 
developed in tiers that begin by classifying only with the least expensive and most easily 
obtainable predictors, and then sequentially expand to use more expensive tests only as 
necessary to achieve categorization. Our hope is that this work, and secondary analyses of 
AURORA data by the scientific field, will achieve improved phenotypes, prediction tools, 
and understanding of molecular mechanisms to inform the development of preventive/ 
ameliorative interventions.
Methodology of the AURORA Study
Study population
More than 140 million Americans are evaluated in US emergency departments (EDs) each 
year.8 One-third of ED visits are for evaluation after trauma exposures (TEs), which 
represent the full range of the most common TEs in the US.9 The vast majority of these 
individuals are discharged to home after evaluation and only about 10% are hospitalized.9 
APNS are similar in these two groups of patients,10–22 which means that the vast majority of 
APNS cases occur among ER patients who are not hospitalized. A similar pattern is found in 
the military, where the great majority of APNS cases are found among those who are 
severely injured.23–29 As a result, focusing on discharged ED patients, although logistically 
more complicated than focusing on hospitalized patients, is the way to capture the vast 
majority of APNS cases from an actuarial perspective. An additional benefit of focusing on 
ED patients discharged to home after evaluation, which is the focus of AURORA, is that the 
key neurobiological, socio-emotional, and cognitive/psychological factors implicated in 
APNS development are less affected than they are among hospitalized patients by such thing 
as hemorrhage30,31, general anesthesia32,33, circadian disruptions34 related to 
hospitalization, and medications, increasing the ability to identify pathogenetic mechanisms 
of APNS. However, AURORA is also recruiting a subsample of patients from those that are 
hospitalized in an effort to increase the external validity of findings and to facilitate 
comparison with other major studies that focus exclusively in patients who were hospitalized 
after ED evaluation.
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Eligibility, screening, and consent
Patients aged 18–75 years who present to the ED within 72 hours of trauma exposure at 
participating ED sites are screened for study eligibility. Some trauma exposures 
automatically qualify for study enrollment, these trauma exposures include motor vehicle 
collision, physical assault, sexual assault, fall greater than 10 feet, or mass casualty 
incidents. Other trauma exposures are also qualifying if (1) the individual responds to a 
screener question that they experienced the exposure as involving actual or threatened 
serious injury, sexual violence, or death, either by direct exposure, witnessing, or learning 
about it and (2) the research assistant agrees that the exposure is a plausible qualifying event.
Exclusion criteria include administration of general anesthesia, long bone fractures, 
laceration with significant hemorrhage, solid organ injury > American Association for the 
Surgery of Trauma Grade 1, not alert and oriented at the time of enrollment, not fluent in 
written or spoken English, visual or auditory impairment precluding completion of web-
based neurocognitive evaluations and/or telephone follow-ups, self-inflicted or occupational 
injury, prisoners, individuals pregnant or breastfeeding, individuals reporting ongoing 
domestic violence, and individuals taking > 20 mg morphine or equivalent per day. To be 
eligible for the study, patients must also have an iOS or Android-compatible smartphone 
with internet access and an email address that they check regularly.
Research assistants (RAs) stationed in participating EDs evaluate patients for enrollment 
and, if eligible, inform patients about the general nature of the study, expectations for 
participation, and the voluntary nature of participation, and discuss risks and benefits before 
seeking written informed consent. As noted above, patients admitted to the hospital from the 
ED and not anticipated to require hospitalization > 72 hours are also eligible to be enrolled 
during hospitalization to increase the external validity of study findings. In addition, patients 
discharged from the ED to home are eligible to return for enrollment within 72 hours of 
discharge. The goal is to enroll 5,000 participants in the study, with adaptive sampling of 
specific trauma subsamples and adjustment of study design over the course of the study as 
necessary to achieve study goals.
Assessments (Tables 1, 2, Figure 3)
ED Assessments—ED assessments are conducted by trained RAs and include blood 
collection, self-report survey, web-based neurocognitive assessment, evoked heart rate and 
skin conductance, and wrist wearable placement. Participants also have an Android/iOS 
smartphone app downloaded onto their smartphone. Specific assessments performed in the 
ED are shown in Table 2.
Self-report evaluations—Participants complete interview and self-administered surveys 
in the ED. Follow-up surveys are completed 2 weeks, 8 weeks, 3 months, 6 months, and 12 
months after initial evaluation via web-based or phone assessments. Domains assessed via 
self-report surveys are shown in Table 2.
Wrist wearable-based assessments—A Verily Study Watch is provided to all study 
participants at the time of enrollment. The Study Watch captures continuous-time 
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photoplethysmogram, 3-dimensional accelerometry, skin conductance, and environmental 
factors including temperature, humidity, atmospheric/air pressure level, and ambient light, 
and also is used to carry out on-demand electrocardiograms in the ED and at 2 weeks, 8 
weeks, 3 months, 6 months, and 12 months after TE. (Table 2). Participants are asked to 
wear the watch at least 21 hours a day for the first 12 weeks of the study and at subsequent 
times that vary by study participant. De-identified and encrypted data are transmitted from 
the participant to the study team via a 3G or 4G LTE watch connectivity hub/charger 
provided to study participants.
Biological specimens-blood (Figure 4)—Biologic specimens collected in the ED from 
all study participants include plasma (10ml EDTA), DNA (PAXgene DNA tube), and RNA 
(PAXgene RNA tube). Following study site collection, samples are shipped to the National 
Institute of Mental Health Repository and Genomics Resources (NIMH RGR) for storage. 
Plasma (10ml EDTA), DNA (PAXgene DNA tube), RNA (PAXgene RNA tube) are 
collected again at 2 weeks and at 6 months from study participants selected to return for 
neuroimaging and psychophysical assessments (maximum 800 individuals at each 
timepoint). An ACD tube is also collected at these return visits. In addition, six months 
following enrollment, repeat plasma (10ml EDTA), DNA (PAXgene DNA tube), and RNA 
(PAXgene RNA tube) samples are also obtained from selected study participants either via 
study participants’ return to enrollment sites or mobile phlebotomy service (maximum 2,200 
individuals).
Smartphone-based assessments—During ED enrollment, research assistants install 
the Mindstrong Discovery™ app onto the participant’s smartphone via download from the 
App Store (iOS users) or from Google Play (Android users). This application intermittently 
prompts participants to complete brief smartphone-based “flash” questionnaires during the 
study and to digitally record their verbal responses to open-ended questions or voice 
recordings of them reading brief neutral passages (Table 2). In addition, this app collects 
continuous-time accelerometry data, keystroke characteristics, time and duration of phone 
calls, time and character length of text messages, text words/symbols used, time and number 
of emails, smartphone screen time, and intermittent GPS data (Table 2). These data are used 
to gain improved understanding of individuals’ experiences and behaviors during APNS 
development. Importantly, all data collected by the smartphone application are de-identified 
and encrypted to ensure participant confidentiality, and the app does not record the numbers 
or identities associated with phone calls or text messages sent or received by the 
participant’s phone.
Biological specimens-saliva—A subset of study participants will undergo saliva 
collection in the ED (Spectrum DNA Collection Kit, 2,000 maximum). Following study site 
collection, de-identified samples are shipped to the National Institute of Mental Health 
Repository and Genomics Resources (NIMH RGR) for storage. Individuals completing 
saliva sample collection in the ED are asked to repeat saliva collection 1, 2, 3, and 4 weeks 
after the ED visit, using kits provided during initial enrollment. De-identified saliva samples 
collected by the participant at home are stored in a liquid-tight biohazard bag provided to the 
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participant at the time of the initial assessment. After the final collection, participants mail 
all 4 samples directly to the NIMH RGR using a pre-paid mailer.
Data extraction—Following enrollment, study site RAs complete a web-based data 
extraction form. This form collects information from hospital medical records related to the 
study participant’s care, including the following: ED arrival and discharge date and time, 
hospital admission and discharge time (if participant is admitted), participant chief 
complaint, radiology evaluations performed and the results of such evaluations, participant 
injuries by body region (e.g., abrasion, contusion), discharge diagnosis, any prescription 
medications that participant was taking prior to the ED visit, vital signs in ED (e.g. blood 
pressure, pulse, respiratory rate), whether patient was seen in the ED and discharged, or 
admitted in the hospital, medications that the participant received in the ED and/or in the 
hospital, and medications that were prescribed at the time of discharge from the ED or 
hospital, and past participant diagnoses listed in the medical record. Description of the event 
that brought the participant to the ED is collected from the medical record.
Neurocognitive assessments—Web-based neurocognitive assessments are hosted 
through the Many Brains Project (http://www.manybrains.net/) and are administered at 
enrollment, within 48 hours after leaving the ED, and with a rotating battery of tests 
delivered via email and text links weekly for the next 8 weeks and then at the end of months 
3, 6, 9 and 12. Areas of neurocognitive function evaluated, which were selected to focus on 
those implicated in the pathogenesis of APNS, are listed in Table 2.
Follow-up in-person ‘deep phenotyping’ assessments—Subsamples of study 
participants who live within driving distance of an AURORA neuroimaging/deep 
phenotyping site are asked to return for in-person evaluations two weeks and six months 
after the ED visit. These in-person sessions include blood collection, structural MRI, 
diffusion tensor imaging, resting state MRI, functional MRI/tasks, neurocognitive 
assessments, and psychophysical evaluation including acoustic startle response, fear 
conditioning and extinction, pressure pain thresholds, suprathreshold pressure pain 
sensitivity (cuff algometry), thermal pain tolerance (cold pressor test), and endogenous pain 
modulation (conditioned pain modulation and temporal summation) (Table 2).
Adaptive sampling
Adaptive sampling is being used throughout AURORA to enrich the sample: (1) Algorithms 
are being developed based on information collected in the ED with the first 500 respondents 
to predict subsequent participant adherence to the study. Probability of being invited to 
participate in the study is then being guided by this prediction algorithm to under-sample 
patients less likely to be adherent to study procedures and to select only individuals likely to 
be adherent for two week neuroimaging/deep phenotyping assessment; (2) Algorithms 
predicting subsequent symptoms based on data collected in the ED are being develop and 
revised iteratively to assign different probabilities of AURORA enrollment to individual 
eligible ED patients to ensure the desired distribution of APNS among study participants; (3) 
Comparable selection algorithms are being used to select participants for 6 month blood 
draws and neuroimaging/deep phenotyping in order to guarantee that this subset of patients 
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has a multivariate distribution on APNS syndromes that is optimized to achieve our aim of 
identifying/classifying common, discrete, homogenous APNS using and/or building on the 
Research Domain Criteria (RDoC) classification system (https://bit.ly/2pudCZH) based on 
both self-report and biomarker data (i.e., biomarkers from different RDoC “units of 
analysis”). The overarching goal of these adaptive sampling procedures is to increase study 
power/efficiency by using case-cohort logic to link the subset of patients receiving the most 
intensive assessments to the broader cohort in a way that creates a rich “molecules to 
behaviors” characterization of the onset and course of specific adverse posttraumatic 
neuropsychiatric sequelae.
Protection of participants
The AURORA Study is an observational study that does not alter or interfere with typical 
receipt of care in any way. All participants receive all of their usual care and treatment 
throughout the study period. Information on type of care and medications received are 
collected in study follow-up surveys. In addition, weekly reports are run that calculate 
change scores for adverse posttraumatic neuropsychiatric sequelae, and participants who 
experience significant worsening of APNS symptoms during the study are contacted by an 
experienced clinician (e.g., experienced social worker) and encouraged to seek medical 
and/or psychiatric care (depending on the sequelae), and when useful, provided information 
regarding how to access care. (Information regarding options for medical and psychiatric 
care in the local area of each study site is maintained by the data coordinating center.) In 
addition, if during interactions with study participants AURORA Study personnel have 
concerns regarding the participant, then the participant is contacted by an experienced 
clinician. The AURORA Study independent medical monitor’s activities include the review 
and approval of standard operating procedures related to the evaluation and management of 
individuals reporting clinical worsening and/or identified by study personnel, and the review 
of all written reports describing participant contacts by experienced clinicians. A great many 
other methods are used to protect patient confidentiality and minimize risks to participants 
during the study, including use of a Certificate of Confidentiality, staff training, use of 
participant ID numbers only on forms, distinct sample numbers on biologic samples, storage 
of study data on secure, firewalled servers, and secure transfer of study data in a HIPAA-
compliant manner.
AURORA Study Analyses
As described in the introduction, the overarching goal of the AURORA Study is to generate 
a longitudinal, multimodal library of brain biology and function after TE with a breadth and 
depth sufficient to overcome the contemporary barriers in classification and ontology that 
stymie scientific progress. It is also hoped that the AURORA study provides a wellspring of 
data for the scientific community to use to advance understanding of APNS. Descriptions of 
planned analyses here will be limited to three broad aims addressed by AURORA 
investigators during the award period.
Aim 1a: Identify/characterize common, discrete, homogeneous APNS using 
and/or building on the RDoC framework—In place of arbitrarily-demarcated 
symptom-based syndromes, unmoored to specific aspects of brain functioning, more discrete 
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APNS grounded in specific, circumscribed components of brain function are needed. We are 
using unsupervised machine learning methods to characterize and structural equation 
modeling and latent growth curve modeling to study the trajectories of these discrete 
homogenous APNS. These analyses are first being carried out using self-report symptom 
assessments collected via in-depth surveys in the ED and at periodic time points (2 weeks, 8 
weeks, 3 months, 6 months, 12 months) after TE and in flash surveys during the 
posttraumatic period (daily for the first week, every other day for weeks 2–12, and weekly 
for weeks 13–52). Once these preliminary models are developed, more novel biobehavioral 
indicators will be explored using the other data being collected via smartphone, wearable, 
neurocognitive tests, and neuroimaging. These analyses will yield trajectories for each 
discrete outcome for each trauma survivor. In addition, after characterizing individual 
trajectories for these discrete outcomes, groups or classes for each discrete APNS outcome 
will be identified using latent growth curve mixture modeling. Classifying discrete APNS 
trajectories into common groups, and identifying the best group membership for each 
individual, allows group-level analyses and will help facilitate later multidimensional 
analyses. Additional analyses will also evaluate the influence of trauma type and participant 
characteristics (e.g., sex) on posttraumatic trajectories, and developmental relationships 
between posttraumatic trajectories (e.g., the influence of hyperarousal trajectories in the 
early post-traumatic period on the transition from acute to chronic pain).
Aim 1b: Identify the most common multidimensional outcomes experienced 
by trauma survivors—After discrete, homogenous APNS have been defined, 
multidimensional analyses will be carried out to identify the most common broad “baskets” 
of discrete APNS phenotypes across traditional APNS silos experienced by trauma 
survivors. This will involve identifying groups or classes of trajectories across the discrete 
APNS outcomes using latent growth curve mixture modeling. Classifying discrete APNS 
trajectories into common groups will result in phenotypes that more accurately reflect the 
experiences of trauma survivors than do traditional categories and will help facilitate later 
multidimensional analyses that evaluate predictive associations involving such things as 
trauma type and participant characteristics and developmental relationships across specific 
trajectories (e.g., associations of hyperarousal trajectories in the early post-traumatic period 
with subsequent transitions from acute to chronic pain). Identifying and characterizing this 
broad landscape will also be a critical step in identifying pathophysiologic mechanisms and 
biobehavioral markers, developing risk prediction tools, and developing better preventive 
and ameliorative interventions for APNS survivors.
Aim 2: Test specific hypotheses regarding the influence of specific pre-
trauma, trauma-related, and recovery-related factors on the discrete and 
multidimensional APNS—To try to advance understanding of APNS pathogenesis and 
identify potential treatment/intervention targets, we will evaluate the influence of specific 
study factors on discrete and/or multidimensional APNS trajectories/outcomes. The 
hypotheses tested will be of three broad types, focused on main effects, mediation, and 
modification. Main effects hypotheses will focus on the influence of a temporally primary 
variable on an outcome. Depending on the hypothesis, the outcome could be a construct 
evaluated either at a point in time or as a trajectory over an interval of time. For example, 
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childhood trauma would be a temporally primary variable that we would expect to predict a 
chronic APNS trajectory across multiple domains. Mediation hypotheses will focus on the 
extent to which the overall association of a predictor with an outcome decreases when an 
intervening variable is controlled. We will test hypotheses such as these by using well-
established procedures for decomposing and separately testing the significance of direct and 
indirect effects among latent variables.35,36 Modifier (interaction) hypotheses will focus on 
the extent to which the effect of a particular predictor varies as a function of some other 
predictor. (For example, we might hypothesize that a specific biological characteristic, such 
as polygenic risk for depression, modifies the impact of death of a loved one in a motor 
vehicle collision on trajectories of an APNS construct by evaluating the significance of 
interactions in a latent curve model.37–39)
Aim 3: Develop tiered clinical decision support algorithms for 
multidimensional APNS outcomes, using ensemble machine learning 
methods and the range of biobehavioral study data collected—An important 
limitation of the current emergency care of trauma survivors is the lack of validated clinical 
decision support tools that identify individuals at high risk for specific APNS outcomes. 
Such tools are critical to advance and support the testing of early preventive/treatment 
interventions to reduce APNS development among those at high risk. When determining 
what constitutes an adverse outcome for a given discrete or multidimensional APNS 
identified via the above work, we will explore a range of different thresholds that represent 
clinically significant distress and dysfunction (e.g., changes in general or domain-specific 
health based on self-reports, changes in neurocognitive function, sleep/physiology, and 
activity). After identifying adverse APNS outcomes using these methods, we will develop 
clinical decision support tools using machine learning (ML) methods in a cross-validated 
training sample that we test in an independent validation sample.40 We will explore a 
number of ML algorithms that we will combine using the super learner ensembling method.
41–45
 As noted above, we will investigate the implications of reducing the number and 
complexity of predictor variables to investigate the value of tiering and targeting. Tiering 
refers to nested ML analyses based on successively more costly predictors, where cost is 
defined in terms of staff time required for administration as well as costs of processing (e.g., 
costs of genetic testing, neuroimaging, etc.) Targeting refers to determining subsets of 
patients that vary in the extent to which prediction accuracy over a clinical decision 
threshold varies depending on a given level of tiering. For example, screening tests are often 
used to determine whether individual patients need more complex and expensive tests. The 
equivalent in our context will be to determine values based on initial models that indicate the 
need for further data. We will also evaluate the temporal range of data needed for optimal 
prediction of various outcomes (i.e., our ability to predict eventual APNS based onl y on 
data obtained in the ED, on ED data i n addition to data obtained in the first week from the 
wearable ad/or phone app, etc.).
Summary and Conclusions
While excitement regarding improved scientific approaches to advance the understanding of 
APNS is often focused around new tools (e.g., the latest molecular or machine learning 
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techniques), the delineation of discrete APNS outcomes indexed to brain function has great 
potential to improve discovery of objective indicators/biomarkers, pathogenic mechanisms, 
and risk prediction tools. Similarly, the identification of multidimensional outcome 
classifications that much more accurately describe a trauma survivor’s APNS has the 
potential to markedly increase the success of precision medicine efforts. Improved APNS 
classification also has the potential to serve as a “common denominator” across different 
medical specialties/groups of APNS investigators, facilitating the exchange of ideas and the 
comparison, testing, and refinement of disparate pathogenic models. AURORA seeks to 
identify discrete and multidimensional APNS outcomes, and to use these improved 
classifications to gain important new insights into APNS pathogenesis and prediction, using 
genomic, neuroimaging, psychophysical, physiological, neurocognitive, digital phenotyping, 
and self-report data collected longitudinally from a large cohort of trauma survivors. Of 
note, only a small proportion of the wealth of data collected in AURORA will be evaluated 
by the investigative team. It is hoped that the dataset (available to the scientific community 
via the NIMH Data Archive) and the extensive library of banked samples collected will 
serve as a wellspring of data to the scientific community studying APNS for many years to 
come.
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Figure 1. 
Trauma survivors with adverse posttraumatic neuropsychiatric sequelae (APNS) have 
traditionally been evaluated in a siloed, syndrome-centered fashion (panel A), in which 
individual syndromes are separately diagnosed and managed. AURORA seeks to provide 
data to help support the ongoing transition to both a more biologically-anchored and patient-
centered approach, in which discrete types of brain dysfunction (panel B) are evaluated, and 
the influence of the overall multidimensional context is considered in the evaluation of 
therapeutic targets and in understanding the response to treatments targeting specific areas of 
dysfunction.
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Figure 2. 
The goal of the AURORA Study is to generate a rich, multilayered biobehavioral library of 
data for each of the most common discrete types of brain/neurobiological dysfunction 
experienced by trauma survivors (Panel A). It is hoped that these data will be valuable in 
achieving a range of goals, including identifying trajectories of predictive biomarkers, 
understanding changes in neurobiology during onset, identifying diagnostic biomarkers, 
and/or understanding markers of worsening symptoms vs. recovery (Panel B).
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Figure 3. 
Study design overview (n=5,000). In-person evaluation includes blood draw, fMRI, and 
psychophysical assessment.
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Figure 4. 
Overview of AURORA Study biological specimens collected. DNA, RNA, and plasma 
samples are collected from all participants (n=5,000 target enrollment) in the Emergency 
Department (ED) in the early aftermath of trauma exposure. Serial saliva samples are 
collected from a subset of participants (n≤2,000) in the ED and 1, 2, 3, and 4 weeks 
following enrollment. DNA, RNA, and plasma are collected again on a subset of participants 
at the 2 week and 6 month deep phenotyping sessions (n≤800) and at the 6 month timepoint 
via individual blood draw (n≤2,200). ACD tubes (for the generation of lymphoproliferative 
cell lines) are collected on a small subset of participants at deep phenotyping sessions.
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Table 1.
Overview of AURORA Study assessments.*
Assessment 
Type
ED W1 W2 W3 W4 W5–
7
W8 W9–
12
M3 M4–5 M6 M7–8 M9 M10–
11
M12
Self-report ● ● ● ● ● ●
Blood ● ●¥
Saliva ●¥ ●¥ ●¥ ●¥ ●¥
Neurocognitive ● ● Weekly rotating battery Quarterly rotating battery
Flash Surveys ● Daily Every other day Weekly rotating assessments
Passive digital Continuous
Wearable Continuous Variable¥
Neuroimaging ●¥ ●¥
Psychophysical ●¥ ●¥
Medical Record ●
*
ED = Emergency Department; W = Week; M = Month
¥Subsample of study participants
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Table 2.
AURORA Study assessments by domain
Assessment & Domain / Task Timepoint
Medical 
Record ED
Self-Report 
Questionnaire ED 2W 8W 3M 6M 12M
 Anxiety 
(PROMIS) ● ● ● ● ● ●
 Depression 
(PROMIS) ● ● ● ● ● ●
 PTSD 
(PCL-5) ● ● ● ● ● ●
 Perceived 
Stress (PSS) ● ● ● ● ● ●
 Current 
alcohol and 
tobacco use 
(PhenX, 
PROMIS) ●
● ● ● ● ●
 Lifetime 
alcohol and 
tobacco use ●
●
 Insomnia 
(ISI) ● ● ● ● ● ●
 Sleep-related 
impairment 
(PROMIS)
● ● ● ● ● ●
 Sleep quality 
(PSQI) ● ● ● ● ● ●
 Nightmares 
(CAPS IV) ● ● ● ● ● ●
 Stress-
induced sleep 
disturbance 
(FIRST) ●
 Panic attack 
during sleep ● ● ● ● ●
 Chronotype 
(CIRENS) ●
 Pain (overall, 
by region) ● ● ● ● ● ●
 Pain 
interference 
(PROMIS)
● ● ● ● ● ●
 Pain 
catastrophizing ● ● ● ● ● ●
 Somatic 
Symptoms ● ● ● ● ● ●
 Disability 
(SDS) ● ● ● ● ● ●
 General 
mental, 
physical health 
(SF-12) ●
● ● ● ● ●
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 Dissociative 
symptoms 
(DES-B)
● ● ●
 Rumination 
(RRQ) ● ● ● ● ●
 Peritraumatic 
distress (PDI)
●
 Expectations 
of recovery
●
 Current 
Medications ● ● ● ● ●
 Emotional 
support 
(PROMIS)
● ● ● ● ●
 Social 
networks
●
 Risk taking 
(RTQ) ● ● ● ● ●
 Resilience 
(CDRS) ● ● ● ● ●
 Mindfulness 
(FFMQ) ● ● ● ● ●
 Impulsivity 
(SUPPS-P) ● ● ● ● ●
Distractibility 
(ASRS)
● ● ● ● ●
 Anxiety 
sensitivity 
(ASI)
●
 Personality 
(BFI, TIPI)
●
 Childhood 
trauma (CTQ) ●
 Lifetime 
trauma (LEC) ●
 Emotional 
problem history 
(AAS Section 
D)
●
 Self-efficacy 
(PROMIS) ●
 Military 
service history ●
 Health 
service 
utilization
● ● ●
 Education 
(PhenX) ●
 Gender 
(PhenX) ●
 DOB ●
 Sex at Birth ●
Socioeconomic 
status
●
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Biologics ED 1W 2W 3W 4W 6M
 DNA ● ● ●
 RNA ● ● ●
 Plasma/
EDTA ● ● ●
 ACD ● ●
 Saliva ● ● ● ● ●
Neurocognitive ED 48 hour W1–12, 3M, 6M, 9M, 12M
Battery 
1
Battery 
2
Battery 
3
Battery 
4
 Simple/
Choice 
Reaction Time
●
 TAU/NIMH 
Dot Probe*
● ●
 Vocabulary 
Test ●
 Gradual 
Onset 
Continuous 
Performance
● ●
 Verbal Paired 
Associates 
Memory
● ●
 Delay 
Discounting ●
 Digit Symbol 
Substitution ● ●
 Multiracial 
Emotion 
Identification 
Test
● ●
 Probabilistic 
Reward ●
 Threat/
Neutral 
Sternberg*
● ●
 Forward 
Digit Span ● ●
 Trauma 
Implicit 
Association 
Test*
● ●
 Cognitive 
Bias Test*
● ●
 Belmont 
Emotional 
Sensitivity Test: 
Anger and 
Happiness*
● ●
Flash Surveys W1 W2 W3 W4 W5 W6 W7 W8 W9 W10 W11 W12 W13-W52
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 Sleep ● ● ● ● ● ● ● ●
W17, Then 
every 7th 
week
 Anxiety, 
depression, 
panic, 
hyperarousal, 
emotional 
numbing
● ● ● ● ● ● ●
W13, then 
every 7th 
week
 Avoidance, 
re-
experiencing, 
rumination
● ● ● ● ● ● ● ●
W18, then 
every 7th 
week
 Somatic 
symptoms ● ● ● ● ● ● ● ● ●
W16, then 
every 7th 
week
 Pain 
rumination ● ● ● ● ● ● ● ●
W15, then 
every 7th 
week
 Self-
regulation, 
disorganization
● ● ● W27,52
 60 second 
audio ● ● ● W20,33,45,51
Smartphone-
based 
Evaluations
W1-M12 
(continuous)
 Phone call 
log ●
 Email log ●
 Text log ●
 Keystrokes ●
 Taps and 
swipes ●
 Location ●
 Word Cloud ●
Accelerometry ●
Wearable W1–12 
(continuous)
M3–12 
(variable)
 Heart rate ● ●
 Autonomic 
Nervous system ● ●
 Sleep ● ●
 Circadian 
rhythm ● ●
 Activity ● ●
 Temperature ● ●
 Humidity ● ●
Atmospheric/ai
r pressure
● ●
 Light ● ●
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In-Person 
Assessments 2W 6M
Startle
 Dark 
Enhanced ● ●
 Acquisition ● ●
 Dot Probe ● ●
 Extinction ● ●
Pain
 Cold Pressor ● ●
 Cuff 
Algometry ● ●
 Temporal 
Summation ● ●
 Pressure Pain 
Threshold ● ●
 Conditioned 
Pain 
Modulation
● ●
fMRI
 Resting state ● ●
 Fearful Faces 
Task ● ●
 Go/NoGo 
Task ● ●
 Reward vs. 
Loss Task ● ●
Structural MRI
 T1 Structural ● ●
DTI ● ●
Blood
 DNA ● ●
 RNA ● ●
 Plasma ● ●
 ACD ● ●
Neurocognitive 
Assessment
 Vocabulary 
Test ●
 Gradual 
Onset 
Continuous 
Performance 
Test
●
 Verbal Paired 
Associates 
Memory Task
●
 Digit Symbol 
Substitution 
Test
●
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 Delay 
Discounting 
Task
●
 Multiracial 
Emotion 
Identification 
Test
●
 Probabilistic 
Reward Task ●
 Forward 
Digit Span ●
*Assessments not completed by full cohort
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